Literature DB >> 32855206

Integrated Genomic Characterization of the Human Immunome in Cancer.

Yongsheng Li1, Brandon Burgman1,2, Daniel J McGrail3, Ming Sun4, Dan Qi5, Sachet A Shukla6, Erxi Wu1,5,7, Anna Capasso1,2, Shiaw-Yih Lin4, Catherine J Wu6, S Gail Eckhardt1,2, Gordon B Mills8,9, Bo Li10, Nidhi Sahni11,12,13, S Stephen Yi14,2,15,16.   

Abstract

Alterations in immune-related pathways are common hallmarks of cancer. A comprehensive understanding of how cancer mutations rewire immune signaling networks and functional output across cancer types is instrumental to realize the full potential of immunotherapy. Here, we systematically interrogated somatic mutations involved in immune signaling that alter immune responses in patients with cancer. To do so, we developed a Network-based Integrative model to Prioritize Potential immune respondER genes (NIPPER). Identified mutations were enriched in essential protein domains and genes identified by NIPPER were associated with responsiveness to multiple immunotherapy modalities. These genes were used to devise an interactome network propagation framework integrated with drug-associated gene signatures to identify potential immunomodulatory drug candidates. Together, our systems-level analysis results help interpret the heterogeneous immune responses among patients and serve as a resource for future functional studies and targeted therapeutics. SIGNIFICANCE: This study demonstrates that integration of multi-omics data can help identify critical molecular determinants for effective targeted therapeutics. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 32855206      PMCID: PMC7642109          DOI: 10.1158/0008-5472.CAN-20-0384

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

2.  Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Authors:  Martin Lauss; Marco Donia; Katja Harbst; Rikke Andersen; Shamik Mitra; Frida Rosengren; Maryem Salim; Johan Vallon-Christersson; Therese Törngren; Anders Kvist; Markus Ringnér; Inge Marie Svane; Göran Jönsson
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

3.  MHC class I-associated peptides derive from selective regions of the human genome.

Authors:  Hillary Pearson; Tariq Daouda; Diana Paola Granados; Chantal Durette; Eric Bonneil; Mathieu Courcelles; Anja Rodenbrock; Jean-Philippe Laverdure; Caroline Côté; Sylvie Mader; Sébastien Lemieux; Pierre Thibault; Claude Perreault
Journal:  J Clin Invest       Date:  2016-11-14       Impact factor: 14.808

4.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Authors:  Eliezer M Van Allen; Diana Miao; Bastian Schilling; Sachet A Shukla; Christian Blank; Lisa Zimmer; Antje Sucker; Uwe Hillen; Marnix H Geukes Foppen; Simone M Goldinger; Jochen Utikal; Jessica C Hassel; Benjamin Weide; Katharina C Kaehler; Carmen Loquai; Peter Mohr; Ralf Gutzmer; Reinhard Dummer; Stacey Gabriel; Catherine J Wu; Dirk Schadendorf; Levi A Garraway
Journal:  Science       Date:  2015-09-10       Impact factor: 47.728

5.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors:  Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

Review 6.  Altered MHC class I antigens in tumors.

Authors:  I Algarra; A Collado; F Garrido
Journal:  Int J Clin Lab Res       Date:  1997

7.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.

Authors:  Aravind Subramanian; Rajiv Narayan; Steven M Corsello; David D Peck; Ted E Natoli; Xiaodong Lu; Joshua Gould; John F Davis; Andrew A Tubelli; Jacob K Asiedu; David L Lahr; Jodi E Hirschman; Zihan Liu; Melanie Donahue; Bina Julian; Mariya Khan; David Wadden; Ian C Smith; Daniel Lam; Arthur Liberzon; Courtney Toder; Mukta Bagul; Marek Orzechowski; Oana M Enache; Federica Piccioni; Sarah A Johnson; Nicholas J Lyons; Alice H Berger; Alykhan F Shamji; Angela N Brooks; Anita Vrcic; Corey Flynn; Jacqueline Rosains; David Y Takeda; Roger Hu; Desiree Davison; Justin Lamb; Kristin Ardlie; Larson Hogstrom; Peyton Greenside; Nathanael S Gray; Paul A Clemons; Serena Silver; Xiaoyun Wu; Wen-Ning Zhao; Willis Read-Button; Xiaohua Wu; Stephen J Haggarty; Lucienne V Ronco; Jesse S Boehm; Stuart L Schreiber; John G Doench; Joshua A Bittker; David E Root; Bang Wong; Todd R Golub
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

8.  AIDA: ab initio domain assembly server.

Authors:  Dong Xu; Lukasz Jaroszewski; Zhanwen Li; Adam Godzik
Journal:  Nucleic Acids Res       Date:  2014-05-15       Impact factor: 16.971

9.  Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes.

Authors:  Aaron Ochel; Marcin Cebula; Mathias Riehn; Upneet Hillebrand; Christoph Lipps; Reinhold Schirmbeck; Hansjörg Hauser; Dagmar Wirth
Journal:  Cell Mol Immunol       Date:  2015-10-12       Impact factor: 11.530

10.  Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Authors:  Chan-Young Ock; Jun-Eul Hwang; Bhumsuk Keam; Sang-Bae Kim; Jae-Jun Shim; Hee-Jin Jang; Sarang Park; Bo Hwa Sohn; Minse Cha; Jaffer A Ajani; Scott Kopetz; Keun-Wook Lee; Tae Min Kim; Dae Seog Heo; Ju-Seog Lee
Journal:  Nat Commun       Date:  2017-10-19       Impact factor: 14.919

View more
  4 in total

1.  Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy.

Authors:  Yan Li; Chen Yang; Zhicheng Liu; Shangce Du; Susan Can; Hailin Zhang; Linmeng Zhang; Xiaowen Huang; Zhenyu Xiao; Xiaobo Li; Jingyuan Fang; Wenxin Qin; Chong Sun; Cun Wang; Jun Chen; Huimin Chen
Journal:  Mol Cancer       Date:  2022-01-02       Impact factor: 27.401

2.  Pediatric Pan-Central Nervous System Tumor Methylome Analyses Reveal Immune-Related LncRNAs.

Authors:  Yongsheng Li; Sicong Xu; Dahua Xu; Tao Pan; Jing Guo; Shuo Gu; Qiuyu Lin; Xia Li; Kongning Li; Wei Xiang
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

3.  Combining Single-Cell and Transcriptomic Data Revealed the Prognostic Significance of Glycolysis in Pancreatic Cancer.

Authors:  Liang Chen; Yunhua Lin; Wei Wei; Yue Wang; Fangyue Li; Wang Du; Zhonghua Yang; Yiming Hu; Xiaomei Ying; Qikai Tang; Jiaheng Xie; Hongzhu Yu
Journal:  Front Genet       Date:  2022-07-05       Impact factor: 4.772

4.  Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.

Authors:  Kunfu Dai; Chao Liu; Ge Guan; Jinzhen Cai; Liqun Wu
Journal:  BMC Cancer       Date:  2022-05-05       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.